Lipid Profiles and Oxidative Stress Parameters in Male and Female Hemodialysis Patients

Overview

Journal Mol Cell Biochem

Publisher Springer

Specialty Biochemistry

Date 2011 May 7

PMID 21547454

Citations 8

Authors

A Osorio

E Ortega

T De Haro

J M Torres

P Sanchez

E Ruiz-Requena

Affiliations

Soon will be listed here.

Abstract

To study atherogenesis markers in patients with stage 5D chronic kidney disease (CKD-5D) on hemodialysis to determine which parameters are modified and whether their behavior differ between male and female patients of similar age. Total cholesterol, triglycerides, glucose, total proteins, HDL-cholesterol, LDL-cholesterol, oxidative modification of low-density lipoprotein-cholesterol, autoantibodies against oxidized low-density lipoproteins-cholesterol, homocysteine (Hcy), folate, and vitamin B12 were measured in male and female controls and CKD-5D patients on hemodialysis for >6 months. The CKD-5D patients had significantly lower cholesterol, LDL-c and ox-LDL levels and significantly higher ox-LDL-AB and Hcy levels versus their respective controls. The reduction in ox-LDL in CKD patients does not imply a lower risk of atherosclerosis. In fact, the risk may be higher due to a greater capture of ox-LDL by macrophage scavenger receptors, which are increased in these patients. Elevated Hcy levels may also be a risk factor for atherosclerosis in male and female CKD-5D patients.

Citing Articles

Shear Wave Elastography in the Diagnosis of Peripheral Neuropathy in Patients With Chronic Kidney Disease Stage 5.

Li X, Sun H, Zhang Z, Liu J, Xu H, Ma L Front Endocrinol (Lausanne). 2022; 13:899822.

PMID: 35813645 PMC: 9259929. DOI: 10.3389/fendo.2022.899822.

Zeng G, Lin J, He Y, Yuan C, Wu Y, Lin Q Int J Gen Med. 2022; 15:3639-3650.

PMID: 35411178 PMC: 8994657. DOI: 10.2147/IJGM.S356476.

Thermopriming reprograms metabolic homeostasis to confer heat tolerance.

Serrano N, Ling Y, Bahieldin A, Mahfouz M Sci Rep. 2019; 9(1):181.

PMID: 30655560 PMC: 6336788. DOI: 10.1038/s41598-018-36484-z.

Influence of Hemodialysis on Lipid Peroxidation, Enzymatic and Non-Enzymatic Antioxidant Capacity in Chronic Renal Failure Patients.

Zargari M, Sedighi O Nephrourol Mon. 2015; 7(4):e28526.

PMID: 26539417 PMC: 4628136. DOI: 10.5812/numonthly.28526.

Association of Plasma Adiponectin and Oxidized Low-Density Lipoprotein with Carotid Intima-Media Thickness in Diabetic Nephropathy.

Tavridou A, Georgoulidou A, Roumeliotis A, Roumeliotis S, Giannakopoulou E, Papanas N J Diabetes Res. 2015; 2015:507265.

PMID: 26064982 PMC: 4443755. DOI: 10.1155/2015/507265.

References

Foley R, Parfrey P, Sarnak M . Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis. 1998; 32(5 Suppl 3):S112-9. DOI: 10.1053/ajkd.1998.v32.pm9820470. View

Stehouwer C, Jakobs C . Abnormalities of vascular function in hyperhomocysteinaemia: relationship to atherothrombotic disease. Eur J Pediatr. 1998; 157 Suppl 2:S107-11. DOI: 10.1007/pl00014293. View

Wanner C, Zimmermann J, Quaschning T, Galle J . Inflammation, dyslipidemia and vascular risk factors in hemodialysis patients. Kidney Int Suppl. 1997; 62:S53-5. View

OByrne D, Devaraj S, Islam K, Collazo R, McDonald L, Grundy S . Low-density lipoprotein (LDL)-induced monocyte-endothelial cell adhesion, soluble cell adhesion molecules, and autoantibodies to oxidized-LDL in chronic renal failure patients on dialysis therapy. Metabolism. 2001; 50(2):207-15. DOI: 10.1053/meta.2001.19486. View

Friedman A, Bostom A, Selhub J, Levey A, Rosenberg I . The kidney and homocysteine metabolism. J Am Soc Nephrol. 2001; 12(10):2181-2189. DOI: 10.1681/ASN.V12102181. View

Valli A, Carrero J, Qureshi A, Garibotto G, Barany P, Axelsson J . Elevated serum levels of S-adenosylhomocysteine, but not homocysteine, are associated with cardiovascular disease in stage 5 chronic kidney disease patients. Clin Chim Acta. 2008; 395(1-2):106-10. DOI: 10.1016/j.cca.2008.05.018. View

Mayer E, Jacobsen D, Robinson K . Homocysteine and coronary atherosclerosis. J Am Coll Cardiol. 1996; 27(3):517-27. DOI: 10.1016/0735-1097(95)00508-0. View

Brunzell J, Albers J, Haas L, Goldberg A, Agadoa L, Sherrard D . Prevalence of serum lipid abnormalities in chronic hemodialysis. Metabolism. 1977; 26(8):903-10. DOI: 10.1016/0026-0495(77)90009-9. View

Higashi Y, Sukhanov S, Anwar A, Shai S, Delafontaine P . IGF-1, oxidative stress and atheroprotection. Trends Endocrinol Metab. 2010; 21(4):245-54. PMC: 2848911. DOI: 10.1016/j.tem.2009.12.005. View

10.

Abdulle A, Gillett M, Abouchacra S, Sabri S, Al Rukhaimi M, Obineche E . Low IGF-1 levels are associated with cardiovascular risk factors in haemodialysis patients. Mol Cell Biochem. 2007; 302(1-2):195-201. DOI: 10.1007/s11010-007-9441-6. View

11.

Dierkes J, Westphal S, Luley C . Serum homocysteine increases after therapy with fenofibrate or bezafibrate. Lancet. 1999; 354(9174):219-20. DOI: 10.1016/S0140-6736(99)02153-4. View

12.

Kushiya F, Wada H, Sakakura M, Mori Y, Gabazza E, Nishikawa M . Effects of lipid abnormalities on arteriosclerosis and hemostatic markers in patients under hemodialysis. Clin Appl Thromb Hemost. 2003; 9(3):203-10. DOI: 10.1177/107602960300900304. View

13.

Lyons T, Jenkins A . Lipoprotein glycation and its metabolic consequences. Curr Opin Lipidol. 1997; 8(3):174-80. DOI: 10.1097/00041433-199706000-00008. View

14.

Stenvinkel P, Heimburger O, Paultre F, Diczfalusy U, Wang T, Berglund L . Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int. 1999; 55(5):1899-911. DOI: 10.1046/j.1523-1755.1999.00422.x. View

15.

Kamijo A, Sugaya T, Hikawa A, Yamanouchi M, Hirata Y, Ishimitsu T . Urinary liver-type fatty acid binding protein as a useful biomarker in chronic kidney disease. Mol Cell Biochem. 2006; 284(1-2):175-82. DOI: 10.1007/s11010-005-9047-9. View

16.

Osorio A, Ortega E, Ruiz-Requena E . Two models of homocysteine behavior in acute myocardial infarction. Clin Biochem. 2008; 41(4-5):277-81. DOI: 10.1016/j.clinbiochem.2007.05.014. View

17.

Sakata N, IMANAGA Y, Meng J, Tachikawa Y, Takebayashi S, Nagai R . Increased advanced glycation end products in atherosclerotic lesions of patients with end-stage renal disease. Atherosclerosis. 1999; 142(1):67-77. DOI: 10.1016/s0021-9150(98)00192-0. View

18.

Bergesio F, Monzani G, Ciuti R, Cirami C, Martinelli F, Salvadori M . Autoantibodies against oxidized LDL in chronic renal failure: role of renal function, diet, and lipids. Nephron. 2001; 87(2):127-33. DOI: 10.1159/000045900. View

19.

van den Akker J, Bredie S, Diepenveen S, van Tits L, Stalenhoef A, van Leusen R . Atorvastatin and simvastatin in patients on hemodialysis: effects on lipoproteins, C-reactive protein and in vivo oxidized LDL. J Nephrol. 2003; 16(2):238-44. View

20.

Schlondorff D . Cellular mechanisms of lipid injury in the glomerulus. Am J Kidney Dis. 1993; 22(1):72-82. DOI: 10.1016/s0272-6386(12)70171-3. View